Literature DB >> 30873541

Recurrent/Intermittent Vaginal and Rectal Chlamydial Infection Following Treatment: A Prospective Cohort Study Among Female Sexually Transmitted Disease Clinic Patients.

Christine M Khosropour1, Olusegun O Soge2,3, Robert Suchland2, Gina Leipertz1, Anna Unutzer1, Rushlenne Pascual3, Kevin Hybiske2, Lindley A Barbee2,4, Lisa E Manhart1,3, Julia C Dombrowski1,2,4, Matthew R Golden1,2,4.   

Abstract

BACKGROUND: Rectal Chlamydia trachomatis (CT) is common among clinic-attending women, but little is known about clearance and health implications of rectal CT.
METHODS: At the municipal sexually transmitted disease clinic in Seattle, Washington, in 2017-2018, we enrolled women at high risk for urogenital CT into an 8-week prospective study. Women received standard CT treatment at enrollment. Women self-collected daily rectal and vaginal specimens for nucleic acid amplification tests (NAATs) and completed weekly sexual exposure diaries. We performed CT culture on the enrollment rectal specimen.
RESULTS: We enrolled 50 women; 13 (26%) tested positive for vaginal (n = 11) and/or rectal (n = 11) CT. Sixty percent of women with rectal CT per NAAT were also culture positive. Median time to CT clearance after azithromycin treatment was 8.0 days for vaginal CT and 7.0 days for rectal CT. Eight women with rectal CT at enrollment had at least 1 rectal CT-positive NAAT after clearance of the initial infection; none reported anal sex.
CONCLUSIONS: Most NAAT-positive rectal infections were culture positive, suggesting active infection. Time to NAAT clearance of rectal and genital tract CT was similar, and intermittent rectal CT positivity was common in the absence of anal sexual exposure. The cause of recurrent/intermittent rectal CT and the clinical implications of these infections require further study.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  azithromycin; chlamydia; doxycycline; sexually transmitted disease

Mesh:

Substances:

Year:  2019        PMID: 30873541      PMCID: PMC6603978          DOI: 10.1093/infdis/jiz113

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  32 in total

1.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

2.  Recurrent chlamydial infections increase the risks of hospitalization for ectopic pregnancy and pelvic inflammatory disease.

Authors:  S D Hillis; L M Owens; P A Marchbanks; L F Amsterdam; W R Mac Kenzie
Journal:  Am J Obstet Gynecol       Date:  1997-01       Impact factor: 8.661

Review 3.  The efficacy of azithromycin and doxycycline for the treatment of rectal chlamydia infection: a systematic review and meta-analysis.

Authors:  Fabian Yuh Shiong Kong; Sepehr N Tabrizi; Christopher Kincaid Fairley; Lenka A Vodstrcil; Wilhelmina M Huston; Marcus Chen; Catriona Bradshaw; Jane S Hocking
Journal:  J Antimicrob Chemother       Date:  2015-01-29       Impact factor: 5.790

4.  An alternative scenario to explain rectal positivity in Chlamydia-infected individuals.

Authors:  Roger G Rank; Laxmi Yeruva
Journal:  Clin Infect Dis       Date:  2015-02-03       Impact factor: 9.079

5.  Azithromycin for rectal chlamydia: is it time to leave azithromycin on the shelf?...Not yet.

Authors:  Stephen J Jordan; William M Geisler
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

6.  Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis.

Authors:  Nastassya L Chandra; Claire Broad; Kate Folkard; Katy Town; Emma M Harding-Esch; Sarah C Woodhall; John M Saunders; S Tariq Sadiq; J Kevin Dunbar
Journal:  Sex Transm Infect       Date:  2018-02-03       Impact factor: 3.519

7.  [Serological and etiological studies on the intestinal psittacosislymphogranuloma infection in sheep].

Authors:  J Storz; W R Thornley
Journal:  Zentralbl Veterinarmed B       Date:  1966-02

8.  A new member of the psittacosis-lymphogranuloma group of viruses that causes infection in calves.

Authors:  C J YORK; J A BAKER
Journal:  J Exp Med       Date:  1951-06       Impact factor: 14.307

9.  Time to clearance of Chlamydia trachomatis RNA and DNA after treatment in patients coinfected with Neisseria gonorrhoeae - a prospective cohort study.

Authors:  Carolien M Wind; Maarten F Schim van der Loeff; Magnus Unemo; Rob Schuurman; Alje P van Dam; Henry J C de Vries
Journal:  BMC Infect Dis       Date:  2016-10-11       Impact factor: 3.090

10.  Monitoring therapy success of urogenital Chlamydia trachomatis infections in women: A prospective observational cohort study.

Authors:  Bart Versteeg; Sylvia M Bruisten; Titia Heijman; Wilma Vermeulen; Martijn S van Rooijen; Alje P van Dam; Maarten F Schim van der Loeff; Henry J C de Vries; Maarten Scholing
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

View more
  3 in total

1.  Antigen-Specific CD4+ T Cell-Derived Gamma Interferon Is Both Necessary and Sufficient for Clearing Chlamydia from the Small Intestine but Not the Large Intestine.

Authors:  Hui Lin; Conghui He; John J Koprivsek; Jianlin Chen; Zhiguang Zhou; Bernard Arulanandam; Zhenming Xu; Lingli Tang; Guangming Zhong
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

2.  Reply to Dukers-Muijrers et al.

Authors:  Christine M Khosropour
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

Review 3.  Controversies and evidence on Chlamydia testing and treatment in asymptomatic women and men who have sex with men: a narrative review.

Authors:  Nicole H T M Dukers-Muijrers; Ymke J Evers; Christian J P A Hoebe; Petra F G Wolffs; Henry J C de Vries; Bernice Hoenderboom; Marianne A B van der Sande; Janneke Heijne; Jeffrey D Klausner; Jane S Hocking; Jan van Bergen
Journal:  BMC Infect Dis       Date:  2022-03-14       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.